Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 10/2017

01-10-2017 | Review

Skeletal complications of rheumatoid arthritis

Authors: L. Heinlen, M. B. Humphrey

Published in: Osteoporosis International | Issue 10/2017

Login to get access

Abstract

Rheumatoid arthritis (RA) is associated with local and systemic inflammation that induces many changes in the skeletal health. Locally, periarticular bone loss and juxta-articular bone erosions may occur while joint ankylosis, generalized bone loss, osteoporosis, and fractures may develop secondary to inflammation. The aim of this narrative review is to summarize the clinical evidence for abnormal skeletal health in RA, the effects of disease modifying anti-rheumatic drugs (DMARDS) on bone health, and the effects of drugs for the prevention or treatment of osteoporosis in the RA population.
Literature
1.
Bellucci E, Terenzi R, La Paglia GM, Gentileschi S, Tripoli A, Tani C et al (2016) One year in review 2016: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 34(5):793–801PubMed
2.
Veale DJ, Orr C, Fearon U (2017) Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol 39:343–354PubMedCrossRef
3.
4.
Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G et al (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford, England) 46(2):342–349CrossRef
5.
Koga T, Okada A, Fukuda T, Hidaka T, Ishii T, Ueki Y et al (2017) Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: a post hoc analysis of a nationwide cohort in Japan. PLoS One 12(5):e0175281PubMedPubMedCentralCrossRef
6.
Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43(8):1831–1835PubMedCrossRef
7.
Carpenter L, Norton S, Nikiphorou E, Jayakumar K, McWilliams DF, Rennie KL et al (2017) Reductions in radiographic progression in early RA over 25-years: changing contribution from RF in 2 multi-centre UK inception cohorts. Arthritis Care Res (Hoboken). doi:10.​1002/​acr.​23217
8.
Kumar S, Pangtey G, Gupta R, Rehan HS, Gupta LK (2017) Assessment of anti-CarP antibodies, disease activity and quality of life in rheumatoid arthritis patients on conventional and biological disease-modifying antirheumatic drugs. Reumatologia 55(1):4–9PubMedPubMedCentral
9.
Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K et al (2015) Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 74(8):1509–1514PubMedCrossRef
10.
Fisher BA, Bang SY, Chowdhury M, Lee HS, Kim JH, Charles P et al (2014) Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease. Ann Rheum Dis 73(4):741–747PubMedCrossRef
11.
Ciubotariu E, Gabay C, Finckh A (2014) Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs? J Rheumatol 41(8):1576–1582PubMedCrossRef
12.
Martel W, Hayes JT, Duff IF (1965) The pattern of bone erosion in the hand and wrist in rheumatoid arthritis. Radiology 84:204–214PubMedCrossRef
13.
McGonagle D, Tan AL, Moller Dohn U, Ostergaard M, Benjamin M (2009) Microanatomic studies to define predictive factors for the topography of periarticular erosion formation in inflammatory arthritis. Arthritis Rheum 60(4):1042–1051PubMedCrossRef
14.
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163PubMedCrossRef
15.
Seror R, Boudaoud S, Pavy S, Nocturne G, Schaeverbeke T, Saraux A et al (2016) Increased Dickkopf-1 in recent-onset rheumatoid arthritis is a new biomarker of structural severity. Data from the ESPOIR Cohort. Sci Rep 6:18421PubMedPubMedCentralCrossRef
16.
Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson DA (2000) Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A 97(6):2791–2796PubMedPubMedCentralCrossRef
17.
Miao CG, Yang YY, He X, Li XF, Huang C, Huang Y et al (2013) Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal 25(10):2069–2078PubMedCrossRef
18.
Ideguchi H, Ohno S, Hattori H, Senuma A, Ishigatsubo Y (2006) Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs. Arthritis Res Ther 8(3):R76PubMedPubMedCentralCrossRef
19.
Sharp JT, Van Der Heijde D, Boers M, Boonen A, Bruynesteyn K, Emery P et al (2003) Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT subcommittee on healing of erosions. J Rheumatol 30(5):1102–1107PubMed
20.
Barbieri F, Zampogna G, Camellino D, Paparo F, Cutolo M, Garlaschi G et al (2016) Ankylosis of the wrist bones in patients with rheumatoid arthritis: a study with extremity-dedicated MRI. Clin Exp Rheumatol 34(1):49–52PubMed
21.
Leden I, Theander J, Svensson B (2008) Small joint ankylosis in rheumatoid arthritis: a vanishing phenomenon or a pathogenetic clue, or both? Ann Rheum Dis 67(12):1786–1787PubMedCrossRef
22.
Eulderink F, Meijers KA (1976) Pathology of the cervical spine in rheumatoid arthritis: a controlled study of 44 spines. J Pathol 120(2):91–108PubMedCrossRef
23.
24.
Iizuka H, Iizuka Y, Okamura K, Yonemoto Y, Mieda T, Takagishi K (2016) Bony ankylosis of the facet joint of the cervical spine in rheumatoid arthritis: its characteristics and relationship to the clinical findings. Mod Rheumatol:1–5
25.
Zhu S, Xu W, Luo Y, Zhao Y, Liu Y (2017) Cervical spine involvement risk factors in rheumatoid arthritis: a meta-analysis. Int J Rheum Dis 20:541–549PubMedCrossRef
26.
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54(10):3104–3112PubMedCrossRef
27.
Brennan SL, Toomey L, Kotowicz MA, Henry MJ, Griffiths H, Pasco JA (2014) Rheumatoid arthritis and incident fracture in women: a case-control study. BMC Musculoskelet Disord 15:13PubMedPubMedCentralCrossRef
28.
Chen B, Cheng G, Wang H, Feng Y (2016) Increased risk of vertebral fracture in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore) 95(45):e5262CrossRef
29.
Ghazi M, Kolta S, Briot K, Fechtenbaum J, Paternotte S, Roux C (2012) Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 23(2):581–587CrossRef
30.
Amin S, Gabriel SE, Achenbach SJ, Atkinson EJ, Melton LJ 3rd (2013) Are young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based study. J Rheumatol 40(10):1669–1676PubMedPubMedCentralCrossRef
31.
Wright NC, Lisse JR, Walitt BT, Eaton CB, Chen Z (2011) Women’s Health Initiative I. Arthritis increases the risk for fractures—results from the Women’s Health Initiative. J Rheumatol 38(8):1680–1688PubMedPubMedCentralCrossRef
32.
Acurcio FA, Moura CS, Bernatsky S, Bessette L, Rahme E (2016) Opioid use and risk of nonvertebral fractures in adults with rheumatoid arthritis: a nested case-control study using administrative databases. Arthritis Rheumatol 68(1):83–91PubMedCrossRef
33.
Klop C, de Vries F, Bijlsma JW, Leufkens HG, Welsing PM (2016) Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis 75(12):2095–2100PubMedPubMedCentralCrossRef
34.
Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224–3229PubMedCrossRef
35.
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum 43(3):522–530PubMedCrossRef
36.
Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O et al (2000) A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian study group on bone mass in rheumatoid arthritis. J Rheumatol 27(11):2582–2589PubMed
37.
Hauser B, Riches PL, Wilson JF, Horne AE, Ralston SH (2014) Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis. Rheumatology (Oxford, England) 53(10):1759–1766CrossRef
38.
Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC (1995) Rheumatoid arthritis and bone mineral density in elderly women. The study of osteoporotic fractures research group. J Bone Miner Res 10(2):257–263PubMedCrossRef
39.
Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344(8914):23–27PubMedCrossRef
40.
Als OS, Gotfredsen A, Riis BJ, Christiansen C (1985) Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis 44(6):406–411PubMedPubMedCentralCrossRef
41.
Sambrook PN, Ansell BM, Foster S, Gumpel JM, Hesp R, Reeve J (1985) Bone turnover in early rheumatoid arthritis 2. Longitudinal bone density studies. Ann Rheum Dis 44(9):580–584PubMedPubMedCentralCrossRef
42.
Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30(7):721–728PubMedCrossRef
43.
Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ et al (2007) Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 66(11):1508–1512PubMedPubMedCentralCrossRef
44.
Hwang J, Lee EK, Ahn JK, Cha HS, Koh EM, Lee J (2017) Bone-density testing interval and transition to osteoporosis in patients with rheumatoid arthritis. Osteoporos Int 28(1):231–237
45.
McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7(6):429–442PubMedCrossRef
46.
Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB et al (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24(9):1572–1585PubMedCrossRef
47.
Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE (2017) IOF Chronic Inflammation and Bone Structure (CIBS) Working Group. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28(2):429-446. doi:10.​1007/​s00198-016-3769-2
48.
Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35(4):309–322PubMedCrossRef
49.
Di Franco M, Barchetta I, Iannuccelli C, Gerardi MC, Frisenda S, Ceccarelli F et al (2015) Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study. BMC Musculoskelet Disord 16:53PubMedPubMedCentralCrossRef
50.
Raczkiewicz A, Kisiel B, Kulig M, Tlustochowicz W (2015) Vitamin D status and its association with quality of life, physical activity, and disease activity in rheumatoid arthritis patients. J Clin Rheumatol Pract Rep Rheum Musculoskeletal Dis 21(3):126–130
51.
Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R (2016) Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther 18(1):226PubMedPubMedCentralCrossRef
52.
Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73(5):854–860PubMedCrossRef
53.
Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122(5):1791–1802PubMedPubMedCentralCrossRef
54.
Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M et al (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59(6):807–815PubMedPubMedCentralCrossRef
55.
Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N (2017) Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int 37(6):1015–1020PubMedCrossRef
56.
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S et al (2017) High frequency of vertebral fracture and low bone quality in patients with rheumatoid arthritis—results from TOMORROW study. Mod Rheumatol 27(3):398–404PubMedCrossRef
57.
El Maghraoui A, Sadni S, Rezqi A, Bezza A, Achemlal L, Mounach A (2015) Does rheumatoid cachexia predispose patients with rheumatoid arthritis to osteoporosis and vertebral fractures? J Rheumatol 42(9):1556–1562PubMedCrossRef
58.
Rodriguez JA, Saddler S, Edelman S, Ranawat CS (1996) Long-term results of total knee arthroplasty in class 3 and 4 rheumatoid arthritis. J Arthroplast 11(2):141–145CrossRef
59.
Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY (2004) Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 86-A(5):963–974PubMedCrossRef
60.
Schrama JC, Espehaug B, Hallan G, Engesaeter LB, Furnes O, Havelin LI et al (2010) Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian arthroplasty register. Arthritis Care Res (Hoboken). 62(4):473–479PubMedCrossRef
61.
Ravi B, Escott B, Shah PS, Jenkinson R, Chahal J, Bogoch E et al (2012) A systematic review and meta-analysis comparing complications following total joint arthroplasty for rheumatoid arthritis versus for osteoarthritis. Arthritis Rheum 64(12):3839–3849PubMedCrossRef
62.
Jamsen E, Virta LJ, Hakala M, Kauppi MJ, Malmivaara A, Lehto MU (2013) The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. Acta Orthop 84(4):331–337PubMedPubMedCentralCrossRef
63.
Moura CS, Abrahamowicz M, Beauchamp ME, Lacaille D, Wang Y, Boire G et al (2015) Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther 17:197PubMedPubMedCentralCrossRef
64.
Asai S, Kojima T, Oguchi T, Kaneko A, Hirano Y, Yabe Y et al (2015) Effects of concomitant methotrexate on large joint replacement in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a multicenter retrospective cohort study in Japan. Arthritis Care Res (Hoboken) 67(10):1363–1370CrossRef
65.
Lescaille G, Coudert AE, Baaroun V, Javelot MJ, Cohen-Solal M, Berdal A et al (2013) Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis? J Rheumatol 40(6):781–786PubMedCrossRef
66.
Conte-Neto N, Bastos AS, Spolidorio LC, Marcantonio RA, Marcantonio E Jr (2011) Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head Face Med 7:7PubMedPubMedCentralCrossRef
67.
Di Fede O, Bedogni A, Giancola F, Saia G, Bettini G, Toia F et al (2016) BRONJ in patients with rheumatoid arthritis: a multicenter case series. Oral Dis 22(6):543–548PubMedCrossRef
68.
Furuya T, Maeda S, Momohara S, Taniguchi A, Yamanaka H (2017) Dental treatments, tooth extractions, and osteonecrosis of the jaw in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. J Bone Miner Metab 35(3):344–350PubMedCrossRef
69.
Barreira SC, Fonseca JE (2016) The impact of conventional and biological disease modifying antirheumatic drugs on bone biology. Rheumatoid arthritis as a case study. Clin Rev Allergy Immunol 51(1):100–109PubMedCrossRef
70.
Rexhepi S, Rexhepi M, Sahatciu-Meka V, Mahmutaj V, Boshnjaku S (2016) The Impact of Low-Dose Diseasemodifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis. Med Arch. 70(2):101–103PubMedPubMedCentralCrossRef
71.
di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M et al (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol. 31(7):1305–1309PubMed
72.
Ornbjerg LM, Ostergaard M, Jensen T, Horslev-Petersen K, Stengaard-Pedersen K, Junker P et al (2017) Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Clin Rheumatol. 36(4):781–789PubMedCrossRef
73.
Pfeil A, Lippold J, Eidner T, Lehmann G, Oelzner P, Renz DM et al (2009) Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. Rheumatol Int. 29(3):287–295PubMedCrossRef
74.
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 65(11):1495–1499PubMedPubMedCentralCrossRef
75.
Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C et al (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 68(3):330–336PubMedCrossRef
76.
Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V et al (2015) Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 67(6):754–764PubMedCrossRef
77.
Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA et al (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 70(2):389–390PubMedCrossRef
78.
Marotte H, Miossec P (2008) Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. Biologics : targets & therapy. 2(4):663–669
79.
Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M (2006) Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 1069:420–427PubMedCrossRef
80.
Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A et al (2015) The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine. 82(2):109–115PubMedCrossRef
81.
Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K et al (2014) The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford, England) 53(5):900–903CrossRef
82.
Hein G, Eidner T, Oelzner P, Rose M, Wilke A, Wolf G et al (2011) Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. 31(2):269–272PubMedCrossRef
83.
Boumans MJ, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM et al (2012) Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 71(1):108–113PubMedCrossRef
84.
Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 15(4):155–160PubMedCrossRef
85.
Roussy JP, Bessette L, Bernatsky S, Rahme E, Lachaine J (2013) Biologic disease-modifying antirheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over. Osteoporos Int. 24(9):2483–2492PubMedCrossRef
86.
Moller Dohn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A et al (2009) Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 68(10):1585–1590PubMedCrossRef
87.
88.
Ramirez J, Narvaez JA, Ruiz-Esquide V, Hernandez-Ganan J, Cuervo A, Inciarte-Mundo J et al (2017) Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: a prospective study with 12 months follow-up. Semin Arthritis Rheum. doi:10.​1016/​j.​semarthrit.​2017.​04.​007
89.
Lisbona MP, Pamies A, Ares J, Almirall M, Navallas M, Solano A et al (2014) Association of bone edema with the progression of bone erosions quantified by hand magnetic resonance imaging in patients with rheumatoid arthritis in remission. J Rheumatol 41(8):1623–1629PubMedCrossRef
90.
Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 24(1):Cd006356
91.
van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 13(10):777–787CrossRef
92.
Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM et al (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67(6):823–828PubMedCrossRef
93.
van der Goes MC, Jacobs JW, Jurgens MS, Bakker MF, van der Veen MJ, van der Werf JH et al (2013) Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 24(4):1429–1436CrossRef
94.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. doi:10.​1002/​acr.​23279
95.
96.
Watt J, Thompson A, Le Riche N, Pope J (2014) There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. Joint Bone Spine 81(4):347–351PubMedCrossRef
97.
Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M et al (2016) Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 27(1):351–359CrossRef
98.
Shin K, Park SH, Park W, Baek HJ, Lee YJ, Kang SW et al (2017) Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther 39(2):268–278 e2PubMedCrossRef
99.
Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N et al (2006) Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 17(5):716–723CrossRef
100.
Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Anno S et al (2017) Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study. Rheumatol Int 37(6):999–1005PubMedCrossRef
101.
Wen L, Kang JH, Yim YR, Lee JW, Lee KE, Park DJ et al (2016) Risk factors for treatment failure in osteoporotic patients with rheumatoid arthritis. Mod Rheumatol 26(2):194–199PubMed
102.
Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7(4):292–304PubMedCrossRef
103.
Nakamura Y, Suzuki T, Yoshida T, Yamazaki H, Kato H. (2017) Vitamin D and Calcium are required during denosumab treatment in osteoporosis with rheumatoid arthritis. Nutrients 9(5)
104.
Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T et al (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (denosumab) in patients with rheumatoid arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75(6):983–990PubMedCrossRef
105.
Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y (2016) Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol 23:1–5
106.
Yue J, Griffith JF, Xiao F, Shi L, Wang D, Shen J et al (2016) Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care Res (Hoboken). doi:10.​1002/​acr.​23133
107.
Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E (2015) Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol 67(6):1456–1464PubMedCrossRef
108.
Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 25(12):2755–2765CrossRef
109.
Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA et al (2017) Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol
110.
Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 22(3):809–816CrossRef
Metadata
Title
Skeletal complications of rheumatoid arthritis
Authors
L. Heinlen
M. B. Humphrey
Publication date
01-10-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 10/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4170-5

Other articles of this Issue 10/2017

Osteoporosis International 10/2017 Go to the issue

Original Article

One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study

Original Article

Atypical subtrochanteric fractures in Korean hip fracture study

Original Article

Bone mineral density in adults with Down syndrome

Original Article

Intake of omega-3 fatty acids contributes to bone mineral density at the hip in a younger Japanese female population

Original Article

Network based subcellular proteomics in monocyte membrane revealed novel candidate genes involved in osteoporosis

Original Article

Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS)